Bristol Myers Squibb is facing renewed confidence questions for its fibrosis program after reported liver-related safety concerns. The company acknowledged a limited number of liver injury events, including a patient death, in testing of admilparant in an FDA-related context. The development adds to the regulatory pressure on antifibrotic candidates as developers seek clarity on signal management, endpoint interpretation, and whether mechanistic hypotheses align with clinical observations. For biotech investors and sponsors with fibrosis portfolios, the incident raises near-term uncertainty about trial continuation and potential label or approval constraints. The broader implication is that late-stage programs may face tighter scrutiny on organ-specific safety, even when efficacy signals remain the dominant focus for development teams.